1. A Novel VPS33B Variant Identified by Exome Sequencing in a Patient with Arthrogryposis-Renal Dysfunction-Cholestasis Syndrome
- Author
-
Jee Hyun Lee, Min J.U. Lee, Kee Hwan Yoo, Baik Lin Eun, Jung Ok Shim, Yoon Lee, Jeong Hee Shin, and Chae R.I. Suh
- Subjects
education.field_of_study ,Pathology ,medicine.medical_specialty ,Mutation ,Arc (protein) ,Hepatology ,business.industry ,Population ,Gastroenterology ,Case Report ,VIPAR ,medicine.disease ,Compound heterozygosity ,medicine.disease_cause ,Arthrogryposis–renal dysfunction–cholestasis syndrome ,Neonatal cholestasis ,Pediatrics, Perinatology and Child Health ,medicine ,VPS33B ,Differential diagnosis ,education ,business ,Exome sequencing - Abstract
Arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome is a rare autosomal recessive multisystemic disease that is associated with the liver, kidney, skin, and central nervous and musculoskeletal systems. ARC occurs as a result of mutations in the VPS33B (Vacuolar protein sorting 33 homolog B) or VIPAR (VPS33B interacting protein, apical-basolateral polarity regulator) genes. A female infant presented with neonatal cholestasis with a severe clinical outcome. She was diagnosed with ARC syndrome using targeted exome sequencing (TES). Exome sequencing revealed compound heterozygous mutations, c.707A>T and c.239+5G>A, in VPS33B, where c.707A>T was a novel variant; the resultant functional protein defects were predicted via in silico analysis. c.239+5G>A, a pathogenic mutation that affects splicing, is found in less than 0.1% of the general population. Invasive techniques, such as liver biopsies, did not contribute to a differential diagnosis of ARC syndrome; thus, early TES together with clinical presentations constituted an apparently accurate diagnostic procedure.
- Published
- 2019